CRL director granted 1,438 shares of stock

Barg Steven reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Barg Steven reported acquisition or exercise transactions in this Form 4 filing.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Steven Barg reported an equity award of 1,438 shares of Common Stock on May 8, 2026. The award is a grant, not an open-market purchase, with a reference price of $177.62 per share.

Following this grant, Barg directly holds 2,865 shares. According to the footnote, the unvested restricted stock units underlying this award will vest on the earlier of May 8, 2027 or the business day before the company’s next annual shareholder meeting.

Insights

Equity compensation analyst

Routine director equity grant with time-based vesting and no open-market trade.

Director Steven Barg received an equity award of 1,438 Common Stock shares at a reference price of $177.62 per share. The Form 4 characterizes this as a grant or award acquisition, indicating compensation rather than a market transaction.

The footnote explains these are unvested restricted stock units that vest on the earlier of May 8, 2027 or the business day prior to the next annual shareholder meeting. After the grant, Barg holds 2,865 shares directly, suggesting a relatively modest position, consistent with routine board compensation.

Insider Trade Summary

Grant/Award: 1,438 shares

Grant/Award 1 txn

Insider Barg Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,438	$177.62	$255K

Holdings After Transaction: Common Stock — 2,865 shares (Direct)

Footnotes (1)

1. F1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

Key Figures

Equity grant size: 1,438 shares Grant reference price: $177.62 per share Post-transaction holdings: 2,865 shares +1 more

4 metrics

Equity grant size 1,438 shares Common Stock grant on May 8, 2026

Grant reference price $177.62 per share Reported transaction price per share

Post-transaction holdings 2,865 shares Total Common Stock directly held after grant

Vesting date May 8, 2027 Earlier of this date or day before next annual meeting

Key Terms

restricted stock units, grant, award, or other acquisition, Common Stock, annual meeting of shareholders

4 terms

restricted stock units financial

"The unvested restricted stock units vest upon the earlier of 5/8/2027..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of shareholders regulatory

"prior to the Company's next annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRL director Steven Barg report in this Form 4 filing?

Director Steven Barg reported receiving a grant of 1,438 shares of Charles River Laboratories Common Stock. The Form 4 identifies this as a grant or award acquisition, reflecting equity-based compensation rather than an open-market stock purchase or sale.

At what price was Steven Barg’s CRL stock award valued?

The reported grant for Steven Barg referenced a price of $177.62 per share for 1,438 shares. This price is typically the grant-date fair value used for accounting, rather than an amount paid by the director in an open-market transaction.

How many CRL shares does Steven Barg hold after this transaction?

After the reported equity award, Steven Barg directly holds 2,865 shares of Charles River Laboratories Common Stock. This total includes the 1,438 shares granted in the transaction, as reflected in the post-transaction holdings reported on the Form 4.

When do Steven Barg’s CRL restricted stock units vest?

The unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before Charles River Laboratories’ next annual shareholder meeting. This time-based vesting schedule ties the award to continued board service over that period.

Was Steven Barg’s CRL Form 4 transaction a market buy or sell?

No, the Form 4 describes the transaction as a grant, award, or other acquisition, not an open-market buy or sell. The 1,438 shares represent equity compensation awarded to the director, with vesting based on future service conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 05:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barg Steven

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		1,438(1)	A	$177.62	2,865	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

	/s/ Steven Barg	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)